TerrAscend (TSNDF) Share-based Compensation (2021 - 2026)
TerrAscend (TSNDF) reported Share-based Compensation of $885000.0 for Q1 2026, down 41.55% year-over-year from $1.5 million in Q1 2025, and down 34.35% quarter-over-quarter from $1.3 million in Q4 2025.
TerrAscend (TSNDF) Share-based Compensation (2021 - 2026) Analysis & Trends
TerrAscend (TSNDF) has 6 years of Share-based Compensation data on file, last reported at $885000.0 in Q1 2026.
- Share-based Compensation for Q1 2026 came in at $885000.0, down 41.55% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.4 million (down 55.03% YoY), and the FY2025 annual result was $5.0 million, down 48.41% from the prior year.
- Share-based Compensation retreated to $885000.0 in Q1 2026 per TSNDF's latest filing, from $1.3 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $4.5 million in Q2 2022 and troughed at $779000.0 in Q2 2025.
- A 5-year average of $2.1 million and a median of $1.8 million in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation soared 140.85% in 2024, then tumbled 68.05% in 2025.
- A 5-year view of Share-based Compensation shows it stood at $1.6 million in 2022, then jumped by 36.63% to $2.2 million in 2023, then declined by 11.26% to $2.0 million in 2024, then plunged by 32.12% to $1.3 million in 2025, then slumped by 34.35% to $885000.0 in 2026.
- Business Quant data shows TSNDF's Share-based Compensation at $885000.0 in Q1 2026, $1.3 million in Q4 2025, and $1.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 43.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 25.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 33.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -395,114.54 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 57.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 21.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 36.33 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 36.86 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 16.04 Mn |
| 10 | TerrAscend | - | - | 34.60 Mn | 885,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 885,000.00 |
| Mar 31, 2026 | 885,000.00 |
| Dec 31, 2025 | 1.35 Mn |
| Dec 31, 2025 | 1.35 Mn |
| Sep 30, 2025 | 1.37 Mn |
| Sep 30, 2025 | 1.37 Mn |
| Jun 30, 2025 | 779,000.00 |
| Jun 30, 2025 | 779,000.00 |
| Mar 31, 2025 | 1.51 Mn |
| Mar 31, 2025 | 1.51 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Dec 31, 2024 | 1.99 Mn |
| Sep 30, 2024 | 4.28 Mn |
| Sep 30, 2024 | 4.28 Mn |
| Jun 30, 2024 | 1.96 Mn |
| Jun 30, 2024 | 1.96 Mn |
| Mar 31, 2024 | 1.49 Mn |
| Mar 31, 2024 | 1.49 Mn |
| Dec 31, 2023 | 2.24 Mn |
| Dec 31, 2023 | 2.24 Mn |